Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/105.JzBkOQ-g.js ...

Merck (MRK) reported fourth quarter and full-year earnings Tuesday, in line with Wall Street estimates. The bad news: Its ...

Merck swung to a quarterly profit as sales grew to beat Wall Street’s estimates, although the drug company’s outlook for 2025 ...

The drug company’s outlook for 2025 and a slide in sales of its HPV vaccine, Gardasil, hit shares.

Shares of Merck are sliding in early trading after the drugmaker surprised Wall Street with a lower-than-expected 2025 sales ...

Merck's stock sank after the company reported fourth-quarter and year-end 2024 earnings this morning. Although it narrowly ...

Merck swung to a fourth-quarter profit as sales grew and even exceeded Wall Street’s estimates, boosted in part by the ...

Merck’s full-year 2025 revenue guidance fell short of what some analysts were expecting, at a range of $64.1 billion to $65.6 ...

Shares of global pharmaceutical company Merck (NYSE:MRK) fell 11% in the morning session after the company reported mixed ...

Merck (MRK) stock was mangled today after the pharmaceutical and vaccine company released its guidance for 2025. The company expects adjusted ...

Citi analyst Geoff Meacham maintained a Buy rating on Merck & Company (MRK – Research Report) today and set a price target of $115.00. The ...

Merck (MRK) stock sank like a stone on Tuesday after the pharmaceutical giant posted poor guidance for the rest of the year.